Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CARL JACK FICHTENBAUM

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1073578951
CMS profile
2920
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$28.43

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $28.43 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $28.43 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CARL JACK FICHTENBAUM

NPI 1073578951 · CMS profile ID 2920

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073578951?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CARL JACK FICHTENBAUM, NPI 1073578951, CMS profile ID 2920. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073578951?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). CARL JACK FICHTENBAUM, NPI 1073578951, CMS profile ID 2920. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073578951?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
CARL JACK FICHTENBAUM, NPI 1073578951, CMS profile ID 2920, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1073578951?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $28.43 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $28.4303/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695413811 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $28.43 1
PY2021 $99.00 1
PY2022 $6,617.41 7
PY2023 $2,560.30 16
PY2024 $249.93 3
PY2025 $2,462.10 13

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,213.04 4
PY2025 Principal investigator $578,272.21 59
PY2024 Recipient $473.50 2
PY2024 Principal investigator $223,284.75 51
PY2023 Recipient $1,149.35 11
PY2023 Principal investigator $65,128.22 19
PY2022 Principal investigator $109,613.44 27
PY2021 Recipient $12,898.30 1
PY2021 Principal investigator $167,018.23 49
PY2020 Principal investigator $181,285.60 70
PY2019 Principal investigator $263,157.10 91

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

91 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Gilead Sciences, Inc. $862.00 12/18/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 676398065
Principal investigator 1 Gilead Sciences, Inc. $1,238.00 12/18/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676398069
Principal investigator 1 ViiV Healthcare Company $1,000.00 12/18/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS CO
A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI No dispute reported 06/30/2026 709021889
Principal investigator 1 ViiV Healthcare Company $390.00 12/17/2019 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI No dispute reported 06/30/2026 1021533231
Principal investigator 1 Gilead Sciences, Inc. $1,039.00 11/20/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676398061
Principal investigator 1 ViiV Healthcare Company $1,638.00 11/13/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS CO
PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ No dispute reported 06/30/2026 669629525
Principal investigator 1 Merck Sharp & Dohme Corporation $0.48 11/08/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects No dispute reported 06/30/2026 691521989
Principal investigator 1 Merck Sharp & Dohme Corporation $40.80 11/08/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects No dispute reported 06/30/2026 691522965
Principal investigator 1 Gilead Sciences, Inc. $791.00 10/23/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 676398047
Principal investigator 1 Gilead Sciences, Inc. $809.00 10/23/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 676398052
Principal investigator 1 Gilead Sciences, Inc. $5,195.00 10/23/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676398057
Principal investigator 1 ViiV Healthcare Company $1,640.00 10/23/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS CO
A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO No dispute reported 06/30/2026 669629915
Principal investigator 1 ViiV Healthcare Company $7,139.34 10/22/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO No dispute reported 06/30/2026 669628927
Principal investigator 1 ViiV Healthcare Company $2,927.79 10/22/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI No dispute reported 06/30/2026 669629083
Principal investigator 1 Gilead Sciences, Inc. $425.00 10/21/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumaratein HIV and HBV Treatment Naive in Hepatitis B and HIV-1 Co-Infected Adults No dispute reported 06/30/2026 676398037
Principal investigator 1 Gilead Sciences, Inc. $425.00 10/21/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 676398041
Principal investigator 1 ViiV Healthcare Company $300.00 10/17/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS CO
PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ No dispute reported 06/30/2026 669628823
Principal investigator 1 ViiV Healthcare Company $1,250.00 10/17/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS CO
PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ No dispute reported 06/30/2026 669628825
Principal investigator 1 ViiV Healthcare Company $1,500.00 10/17/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS CO
PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ No dispute reported 06/30/2026 669628827
Principal investigator 1 ViiV Healthcare Company $390.00 10/17/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS CO
PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ No dispute reported 06/30/2026 669628829
Principal investigator 1 Gilead Sciences, Inc. $425.00 10/16/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676398033
Principal investigator 1 Merck Sharp & Dohme Corporation $8,229.84 10/16/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects No dispute reported 06/30/2026 691538401
Principal investigator 1 ViiV Healthcare Company $13,432.12 10/11/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS CO LLC
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 669629223
Principal investigator 1 Merck Sharp & Dohme Corporation $38.40 10/08/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects No dispute reported 06/30/2026 691519819
Principal investigator 1 Merck Sharp & Dohme Corporation $1.28 10/08/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects No dispute reported 06/30/2026 691521955
Principal investigator 1 Merck Sharp & Dohme Corporation $27.20 10/08/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects No dispute reported 06/30/2026 691522271
Principal investigator 1 Merck Sharp & Dohme Corporation $27.20 10/08/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects No dispute reported 06/30/2026 691522275
Principal investigator 1 Merck Sharp & Dohme Corporation $27.20 10/08/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects No dispute reported 06/30/2026 691522279
Principal investigator 1 Merck Sharp & Dohme Corporation $3.48 10/08/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects No dispute reported 06/30/2026 691522283
Principal investigator 1 Gilead Sciences, Inc. $809.00 09/18/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 676398027
Principal investigator 1 Merck Sharp & Dohme Corporation $18.00 09/10/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects No dispute reported 06/30/2026 691458501
Principal investigator 1 Gilead Sciences, Inc. $3,495.00 08/21/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676398023
Principal investigator 1 ViiV Healthcare Company $3,252.60 08/14/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS CO LLC
PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ No dispute reported 06/30/2026 669628045
Principal investigator 1 Amgen Inc. $183.34 08/08/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
Ph3b Evolocumab in HIV Patients No dispute reported 06/30/2026 675795155
Principal investigator 1 ViiV Healthcare Company $2,251.98 07/25/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI No dispute reported 06/30/2026 669627547
Principal investigator 1 ViiV Healthcare Company $13,294.31 07/19/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS CO LLC
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 669627889
Principal investigator 1 ViiV Healthcare Company $3,966.30 07/18/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO No dispute reported 06/30/2026 669628513
Principal investigator 1 Gilead Sciences, Inc. $1,212.00 07/17/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 676398009
Principal investigator 1 Gilead Sciences, Inc. $2,530.00 07/17/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 676398015
Principal investigator 1 Gilead Sciences, Inc. $3,495.00 07/17/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676398019
Principal investigator 1 Amgen Inc. $701.00 07/15/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
Ph3b Evolocumab in HIV Patients No dispute reported 06/30/2026 675778015
Principal investigator 1 ViiV Healthcare Company $150.00 07/09/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI No dispute reported 06/30/2026 669627545
Principal investigator 1 Janssen Research & Development, LLC $4,110.00 06/10/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor Combined With Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically-suppressed, Human Immunodeficiency Virus Type 1 Infected Subjects No dispute reported 06/30/2026 654263161
Principal investigator 1 Merck Sharp & Dohme Corporation $0.32 06/10/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects No dispute reported 06/30/2026 691411713
Principal investigator 1 Merck Sharp & Dohme Corporation $38.40 06/10/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects No dispute reported 06/30/2026 691414295
Principal investigator 1 Merck Sharp & Dohme Corporation $3.48 06/10/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects No dispute reported 06/30/2026 691415415
Principal investigator 1 Gilead Sciences, Inc. $3,117.00 05/22/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676398002
Principal investigator 1 ViiV Healthcare Company $3,239.73 05/17/2019 Non-covered Recipient Entity
UC HEALTH
PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ No dispute reported 06/30/2026 669628043
Principal investigator 1 Gilead Sciences, Inc. $1,425.00 05/15/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 676397995
Principal investigator 1 Gilead Sciences, Inc. $1,425.00 05/15/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 676397999
Principal investigator 1 ViiV Healthcare Company $1,300.00 05/09/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI No dispute reported 06/30/2026 669627837
Principal investigator 1 ViiV Healthcare Company $7,986.42 05/01/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS CO LLC
A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO No dispute reported 06/30/2026 669628515
Principal investigator 1 Merck Sharp & Dohme Corporation $4,800.74 04/29/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects No dispute reported 06/30/2026 691456723
Principal investigator 1 ViiV Healthcare Company $3,227.79 04/25/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI No dispute reported 06/30/2026 669626777
Principal investigator 1 ViiV Healthcare Company $1,250.00 04/24/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS CO LLC
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 669627275
Principal investigator 1 Gilead Sciences, Inc. $1,314.00 04/17/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 676397979
Principal investigator 1 Gilead Sciences, Inc. $1,867.00 04/17/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 676397985
Principal investigator 1 Gilead Sciences, Inc. $3,117.00 04/17/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676397989
Principal investigator 1 ViiV Healthcare Company $17,326.39 04/15/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS CO LLC
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 669627273
Principal investigator 1 Merck Sharp & Dohme Corporation $2,057.46 04/03/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects No dispute reported 06/30/2026 691456721
Principal investigator 1 Gilead Sciences, Inc. $2,240.00 04/01/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 676397973
Principal investigator 1 Amgen Inc. $3,097.00 03/26/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
Ph3b Evolocumab in HIV Patients No dispute reported 06/30/2026 675795157
Principal investigator 1 ViiV Healthcare Company $1,170.00 03/26/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI No dispute reported 06/30/2026 669626767
Principal investigator 1 ViiV Healthcare Company $3,000.00 03/26/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS CO LLC
A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI No dispute reported 06/30/2026 669627175
Principal investigator 1 PFIZER INC. $1,000.00 03/21/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
AN INTERNATIONAL MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY OF THE SAFETY OF MARAVIROC USED WITH OPTIMIZED BACKGROUND THERAPY IN TREATMENTEXPERIENCED HIV1 INFECTED PATIENTS No dispute reported 06/30/2026 671638991
Principal investigator 1 Gilead Sciences, Inc. $1,867.00 03/20/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 676397963
Principal investigator 1 Gilead Sciences, Inc. $3,350.00 03/20/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676397969
Principal investigator 1 Merck Sharp & Dohme Corporation $1,082.12 03/19/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects No dispute reported 06/30/2026 691294859
Principal investigator 1 Merck Sharp & Dohme Corporation $945.60 03/12/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects No dispute reported 06/30/2026 691324741
Principal investigator 1 Janssen Research & Development, LLC $200.00 03/04/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor Combined With Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically-suppressed, Human Immunodeficiency Virus Type 1 Infected Subjects No dispute reported 06/30/2026 654263159
Principal investigator 1 Merck Sharp & Dohme Corporation $945.60 02/28/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects No dispute reported 06/30/2026 691324739
Principal investigator 1 Gilead Sciences, Inc. $874.00 02/20/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 676397945
Principal investigator 1 Gilead Sciences, Inc. $921.00 02/20/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 676397951
Principal investigator 1 Gilead Sciences, Inc. $2,100.00 02/20/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen containing Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV 1 Infected Subjects who are Virologically Suppressed No dispute reported 06/30/2026 676397955
Principal investigator 1 Gilead Sciences, Inc. $16,005.00 02/20/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676397959
Principal investigator 1 ViiV Healthcare Company $2,633.67 02/15/2019 Non-covered Recipient Entity
UC HEALTH
PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ No dispute reported 06/30/2026 669626537
Principal investigator 1 Gilead Sciences, Inc. $13,500.00 02/04/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676397939
Principal investigator 1 ViiV Healthcare Company $390.00 02/01/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI No dispute reported 06/30/2026 669627173
Principal investigator 1 Merck Sharp & Dohme Corporation $780.00 01/31/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects No dispute reported 06/30/2026 691311531
Principal investigator 1 Amgen Inc. $10,013.76 01/28/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
Ph3b Evolocumab in HIV Patients No dispute reported 06/30/2026 675795159
Principal investigator 1 Gilead Sciences, Inc. $1,455.00 01/28/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 676397929
Principal investigator 1 Gilead Sciences, Inc. $6,568.00 01/28/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676397933
Principal investigator 1 Merck Sharp & Dohme Corporation $110.08 01/28/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI, INFECTIOUS DISEASE RESEARCH
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Na ve HIV-1 Infected Subjects No dispute reported 06/30/2026 691415411
Principal investigator 1 Amgen Inc. $24,264.00 01/26/2019 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY, LLC
Ph3b Evolocumab in HIV Patients No dispute reported 06/30/2026 675794796
Principal investigator 1 ViiV Healthcare Company $6,346.08 01/22/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO No dispute reported 06/30/2026 669626491
Principal investigator 1 ViiV Healthcare Company $1,951.98 01/17/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
A MULTI-ARM, PHASE 3, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND CLI No dispute reported 06/30/2026 669626769
Principal investigator 1 ViiV Healthcare Company $9,145.82 01/17/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS CO LLC
A PHASE IIIB, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY No dispute reported 06/30/2026 669626967
Principal investigator 1 ViiV Healthcare Company $250.00 01/17/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS CO LLC
A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO No dispute reported 06/30/2026 669628485
Principal investigator 1 Gilead Sciences, Inc. $2,100.00 01/09/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in HIV-1 Infected Adults on Chronic Hemodialysis No dispute reported 06/30/2026 676397923
Principal investigator 1 Gilead Sciences, Inc. $425.00 01/03/2019 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY
A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naive Adults No dispute reported 06/30/2026 676397917
Principal investigator 1 ViiV Healthcare Company $250.00 01/03/2019 Non-covered Recipient Entity
UC HEALTH
PH 3 HIV TWO-YEAR NON-INFERIORITY COMPARED TO STANDARD OF CARE SAFETY/ No dispute reported 06/30/2026 669626535